Cantargia has submitted the first application to start a phase I/IIa clinical trial with the antibody CAN04 in patients, primarily with non-small cell lung cancer or pancreatic cancer.
The trial is planned to be performed at several centres in the BeNeLux and Scandinavia. The goal is to start recruitment as quickly as possible after regulatory approval.
Cantargia has formally applied to start a phase I/IIa clinical trial with its proprietary antibody CAN04, directed towards the molecular target IL1RAP, in patients with cancer. The indications of primary focus in this trial are non-small cell lung cancer and pancreatic cancer. The primary endpoint will be safety, other endpoints include pharmacokinetics, efficacy and biomarkers. The trial is planned to be conducted as a multicentre trial in the BeNeLux and Scandinavia. Applications are now being submitted on a national level to regulatory authorities as well as ethics committees and with independent, formal approval processes in the different territories the review periods may differ.
The clinical trial has been named CANFOUR and as the process moves forward, trial details and potential updates will continuously be published at www.clinicaltrials.gov.
“The project is following communicated plans and have taken another step towards the goal of investigating the CAN04 antibody in patients with life-threatening diseases”, Göran Forsberg, CEO of Cantargia, says. “I like to thank the Cantargia team and our collaborators for their dedication to reach this important milestone”.
